Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-09-22), Nanoform Finland's 3-1 Month Momentum % is 15.75%.
The industry rank for Nanoform Finland's 3-1 Month Momentum % or its related term are showing as below:
STU:4YL's 3-1 Month Momentum % is ranked better than 74.48% of 1383
companies
in the Biotechnology industry
Industry Median: 0.47
vs STU:4YL: 15.75
Nanoform Finland (STU:4YL) 3-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Nanoform Finland 3-1 Month Momentum % Related Terms
STU:4YL vs VRTX, REGN, MRNA: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Nanoform Finland's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nanoform Finland 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nanoform Finland's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Nanoform Finland's 3-1 Month Momentum % falls into.
Nanoform Finland (STU:4YL) 3-1 Month Momentum % Calculation
3-1 Month Momentum % is calculated as following:
3-1 Month Momentum %
=
( Price 1-month ago
/
Price 3-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nanoform Finland (STU:4YL) has a 3-1 Month Momentum % of 15.75% as of Sep. 22, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Nanoform Finland and its competitors. According to the industry distribution chart, Nanoform Finland ranks #353 out of 1383 companies in the Biotechnology industry, placing it in the top 25.5%.
Is Nanoform Finland's 3-1 Month Momentum % too high?
Nanoform Finland's current 3-1 Month Momentum % is 15.75%. The Biotechnology industry median 3-1 Month Momentum % is 0.47. Nanoform Finland's value of 15.75% is 3251.1% above this industry median. Based on the distribution chart, Nanoform Finland ranks #353 out of 1383 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Nanoform Finland has a GF Score™ of 71/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Nanoform Finland's 3-1 Month Momentum % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Nanoform Finland ranks #353 out of 1383 companies for 3-1 Month Momentum %. This puts Nanoform Finland in the upper half of its industry. The industry median 3-1 Month Momentum % is 0.47. Nanoform Finland's value of 15.75% is 3251.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
The median 3-1 Month Momentum % among Biotechnology companies is 0.47, based on 1,383 companies in the industry. Companies in the top quartile (top 25%) have a 3-1 Month Momentum % significantly above this median, while those in the bottom quartile fall well below. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nanoform Finland's current 3-1 Month Momentum % of 15.75% is 3251.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Nanoform Finland and its competitors. For the Biotechnology industry, the median 3-1 Month Momentum % is 0.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nanoform Finland's current 3-1 Month Momentum % is 15.75%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nanoform Finland stock overvalued right now?
Based on GuruFocus' analysis, Nanoform Finland (STU:4YL) is currently considered Possible Value Trap. The stock's GF Value™ is €1.87, compared to a current price of €0.87 — trading 53.6% below its estimated fair value. The current 3-1 Month Momentum % is 15.75% and 3251.1% above the Biotechnology industry median of 0.47. Nanoform Finland's overall GF Score™ is 71/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Nanoform Finland (STU:4YL), the current 3-1 Month Momentum % is 15.75% as of Sep. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nanoform Finland (STU:4YL) Overvalued in 2026?
Based on GuruFocus' analysis, Nanoform Finland stock appears to be undervalued.
The current stock price of €0.87 is trading 53.6% below its estimated GF Value™ of €1.87.
GuruFocus considers Nanoform Finland to be Possible Value Trap.
Key valuation signals for STU:4YL:
3-1 Month Momentum %: 15.75%
GF Value™: €1.87 vs. price of €0.87 (53.6% below fair value)
Industry Position: 3251.1% above the Biotechnology median (#353 of 1383)
No single metric tells the full story. See the STU:4YL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nanoform Finland PLC is a nanoparticle medicine-enabling company. The company works together with pharma and biotech partners to reduce attrition in clinical trials and enhance their molecules' formulation performance through its nano-forming services. Its patented and scalable Controlled Expansion of Supercritical Solutions (CESS) technology produces nano-formed API particles as small as 10nm. This enables poorly soluble molecules in the pharmaceutical pipeline to progress into clinical development by increasing their rate of dissolution and improving their bioavailability. Its technology provides novel opportunities in many value-enhancing drug delivery applications. Geographically, the company generates maximum revenue from Europe, followed by the United States and other regions.
71GF Score
Get the complete analysis for STU:4YL
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:4YL has been successfully added to your 
